{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T14:41:12Z","timestamp":1792075272786,"version":"4.4.0"},"reference-count":19,"publisher":"Wiley","issue":"11","license":[{"start":{"date-parts":[[2022,7,22]],"date-time":"2022-07-22T00:00:00Z","timestamp":1658448000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007543","name":"Agence Nationale de S\u00e9curit\u00e9 du M\u00e9dicament et des Produits de Sant\u00e9","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007543","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006436","name":"Celgene","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006436","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004312","name":"Eli Lilly and Company","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004312","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008897","name":"Janssen Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008271","name":"LEO Pharma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008271","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009945","name":"Merck KGaA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009945","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004336","name":"Novartis","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004336","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Acad Dermatol Venereol"],"published-print":{"date-parts":[[2022,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Biologics are the cornerstone of treatment of patients with moderate\u2010to\u2010severe plaque psoriasis and switches between biologics are frequently needed to maintain clinical improvement over time.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The main purpose of this study was to describe precisely switches between biologics and how their pattern changed over time with the recent availability of new biologic agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We included patients receiving a first biologic agent in the Psobioteq multicenter cohort of adults with moderate\u2010to\u2010severe psoriasis receiving systemic treatment. We described switches between biologics with chronograms, Sankey and Sunburst diagrams, assessed cumulative incidence of first switch by competing risks survival analysis and reasons for switching. We assessed the factors associated with the type of switch (intra\u2010class \u2013 i.e. within the same therapeutic class \u2010 vs. inter\u2010class) in patients switching from a TNF\u2010alpha inhibitor using multivariate logistic regression.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>A total of 2153 patients was included. The cumulative incidence of switches from first biologic was 34% at 3\u2009years. Adalimumab and ustekinumab were the most prescribed biologic agents as first and second lines of treatment. The main reason for switching was loss of efficacy (72%), followed by adverse events (11%). Patients receiving a TNF\u2010alpha inhibitor before 2016 mostly switched to ustekinumab, whereas those switching in 2016 or after mostly switched to an IL\u201017 inhibitor. Patients switching from a first\u2010line TNF\u2010alpha inhibitor before 2016 were more likely to switch to another TNF\u2010alpha inhibitor compared with patients switching since 2018. Patients switching from etanercept were more likely to receive another TNF\u2010alpha inhibitor rather than another therapeutic class of bDMARD compared with patients switching from adalimumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>This study described the switching patterns of biologic treatments and showed how they changed over time, due to the availability of the new biologic agents primarily IL\u201017 inhibitors.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/jdv.18409","type":"journal-article","created":{"date-parts":[[2022,7,6]],"date-time":"2022-07-06T15:03:25Z","timestamp":1657119805000},"page":"2101-2112","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":34,"title":["<b>Switches between biologics in patients with moderate\u2010to\u2010severe psoriasis: results from the French cohort<\/b>\n                    <scp>PSOBIOTEQ<\/scp>"],"prefix":"10.1111","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1272-5813","authenticated-orcid":false,"given":"R.","family":"Curmin","sequence":"first","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Guillo","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi) Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Y.","family":"De Rycke","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi) Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Bachelez","sequence":"additional","affiliation":[{"name":"Dermatologie, AP\u2010HP H\u00f4pital Saint Louis  Paris France"},{"name":"Sorbonne Paris Cit\u00e9 Universitaire Paris Diderot  Paris France"},{"name":"UMR INSERM 1163, Institut Imagine  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6150-1229","authenticated-orcid":false,"given":"M.","family":"Beylot\u2010Barry","sequence":"additional","affiliation":[{"name":"Dermatologie CHU Bordeaux &amp; INSERM U 1053 Bordeaux University  Bordeaux France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Beneton","sequence":"additional","affiliation":[{"name":"Dermatologie CH Le Mans  Le Mans France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8400-4310","authenticated-orcid":false,"given":"O.","family":"Chosidow","sequence":"additional","affiliation":[{"name":"Dermatologie, AP\u2010HP, H\u00f4pitaux universitaires Henri Mondor, D\u00e9partement de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE Universit\u00e9 Paris\u2010Est Cr\u00e9teil, UPEC  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Dupuy","sequence":"additional","affiliation":[{"name":"Dermatologie CHU Pontchaillou  Rennes France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5734-0255","authenticated-orcid":false,"given":"P.","family":"Joly","sequence":"additional","affiliation":[{"name":"Dermatologie CHU Rouen  Rouen France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2995-7928","authenticated-orcid":false,"given":"D.","family":"Jullien","sequence":"additional","affiliation":[{"name":"Dermatologie, Hospices Civils de Lyon, H\u00f4pital E. Herriot Universit\u00e9 Lyon\u20101  Lyon France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0870-9132","authenticated-orcid":false,"given":"M.A.","family":"Richard","sequence":"additional","affiliation":[{"name":"Dermatologie, EA 3279: CEReSS \u2010 Health Service Research and Quality of Life Center, Timone Hospital, Assistance Publique H\u00f4pitaux de Marseille Aix\u2010Marseille University  Marseille France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Viguier","sequence":"additional","affiliation":[{"name":"Dermatologie\u2010V\u00e9n\u00e9r\u00e9ologie H\u00f4pital Robert Debr\u00e9  Reims France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1267-5270","authenticated-orcid":false,"given":"E.","family":"Sbidian","sequence":"additional","affiliation":[{"name":"Dermatologie, AP\u2010HP, H\u00f4pitaux universitaires Henri Mondor, D\u00e9partement de Dermatologie, UPEC, INSERM, Centre d'Investigation Clinique 1430, EA 7379 EpidermE Universit\u00e9 Paris\u2010Est Cr\u00e9teil, UPEC  Cr\u00e9teil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Paul","sequence":"additional","affiliation":[{"name":"Dermatologie CHU and Toulouse University  Toulouse France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5780-1827","authenticated-orcid":false,"given":"E.","family":"Mah\u00e9","sequence":"additional","affiliation":[{"name":"Dermatologie H\u00f4pital Victor Dupouy  Argenteuil France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"F.","family":"Tubach","sequence":"additional","affiliation":[{"name":"INSERM, Institut Pierre Louis d'Epid\u00e9miologie et de Sant\u00e9 Publique, AP\u2010HP, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie (Cephepi) Sorbonne Universit\u00e9  Paris France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"the PSOBIOTEQ Study Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2022,7,22]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.m1590"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14959"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1101\/cshperspect.a015354"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.15340"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1159\/000504839"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2019.1698699"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40261-017-0603-3"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.18203\/issn.2455-4529.IntJResDermatol20201587"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2021.06.878"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.2340\/00015555-3765"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13860"},{"key":"e_1_2_8_13_1","first-page":"218","article-title":"Exploring patient path through Sankey diagram: a proof of concept","volume":"270","author":"Lamer A","year":"2020","journal-title":"Stud Health Technol Inform"},{"key":"e_1_2_8_14_1","unstructured":"RouxJ.Care pathways of persons with multiple sclerosis in France using administrative data[Internet]2018. Available from:https:\/\/tel.archives\u2010ouvertes.fr\/tel\u201002379451"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.14406"},{"key":"e_1_2_8_16_1","unstructured":"Cohorte multicentrique de patients recevant un traitement syst\u00e9mique (conventionnel ou bioth\u00e9rapie) pour un psoriasis cutan\u00e9 mod\u00e9r\u00e9 \u00e0 s\u00e9v\u00e8re \/ Portail Epidemiologie \u2010 France \u00a6 Health Databases [Internet]. [cited 2021 Aug 23]. Available from:https:\/\/epidemiologie\u2010france.aviesan.fr\/epidemiologie\u2010france\/fiches\/cohorte\u2010multicentrique\u2010de\u2010patients\u2010recevant\u2010un\u2010traitement\u2010systemique\u2010conventionnel\u2010ou\u2010biotherapie\u2010pour\u2010un\u2010psoriasis\u2010cutane\u2010modere\u2010a\u2010severe"},{"key":"e_1_2_8_17_1","first-page":"7","article-title":"Current knowledge on psoriasis and autoimmune diseases","volume":"6","author":"Ayala\u2010Font\u00e1nez N","year":"2016","journal-title":"Psoriasis Auckl NZ"},{"key":"e_1_2_8_18_1","first-page":"CD011535","article-title":"Systemic pharmacological treatments for chronic plaque psoriasis: a network meta\u2010analysis","volume":"4","author":"Sbidian E","year":"2021","journal-title":"Cochrane Database Syst Rev"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.16102"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjd.15027"}],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18409","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/jdv.18409","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/jdv.18409","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,20]],"date-time":"2023-08-20T15:02:25Z","timestamp":1692543745000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/jdv.18409"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7,22]]},"references-count":19,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["10.1111\/jdv.18409"],"URL":"https:\/\/doi.org\/10.1111\/jdv.18409","archive":["Portico"],"relation":{},"ISSN":["0926-9959","1468-3083"],"issn-type":[{"value":"0926-9959","type":"print"},{"value":"1468-3083","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,7,22]]},"assertion":[{"value":"2022-02-22","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-05-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-22","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}